BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 27569927)

  • 1. Impact of donor-specific antibody with low mean fluorescence intensity on allograft outcomes in kidney transplant.
    Kitpermkiat R; Kantachuvesiri S; Thotsiri S; Thammanichanond D; Rostaing L; Wiwattanathum P
    Transpl Immunol; 2024 Jun; 84():102054. PubMed ID: 38750972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.
    Viglietti D; Loupy A; Vernerey D; Bentlejewski C; Gosset C; Aubert O; Duong van Huyen JP; Jouven X; Legendre C; Glotz D; Zeevi A; Lefaucheur C
    J Am Soc Nephrol; 2017 Feb; 28(2):702-715. PubMed ID: 27493255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender disparities in allograft access due to HLA-sensitization in multiparous women.
    Fingrut WB; Davis E; Archer A; Brown S; Devlin S; Chinapen S; Scaradavou A; Politikos I; Blouin AG; Shaffer BC; Barker JN
    Blood Adv; 2024 Jan; 8(2):403-406. PubMed ID: 38029385
    [No Abstract]   [Full Text] [Related]  

  • 4. De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.
    Cioni M; Nocera A; Innocente A; Tagliamacco A; Trivelli A; Basso S; Quartuccio G; Fontana I; Magnasco A; Drago F; Gurrado A; Guido I; Compagno F; Garibotto G; Klersy C; Verrina E; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
    J Immunol Res; 2017; 2017():1747030. PubMed ID: 28367453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Specific HLA Antibodies: A Review of Data Published in 2016.
    Idica A; Everly MJ
    Clin Transpl; 2016; 32():13-22. PubMed ID: 28564519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
    Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
    Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
    Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of C1q Binding Status With De Novo HLA Antibody Clinical Features and Allograft Function in Kidney Transplantation Patients During Eight Years of Dynamic Follow-up.
    Wei X; Yuan X; Sun M; Pan Z; Hu L; Wang L; He J; Hou J
    Transplant Proc; 2016; 48(6):1944-54. PubMed ID: 27569927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Humoral Theory to Performant Risk Stratification in Kidney Transplantation.
    Lefaucheur C; Viglietti D; Mangiola M; Loupy A; Zeevi A
    J Immunol Res; 2017; 2017():5201098. PubMed ID: 28133619
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.